OT-82 is under clinical development by OncoTartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect OT-82’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OT-82 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
OT-82 is under development for the treatment of adult and pediatric hematological malignancy like ALL, Ewing sarcoma, melanoma, acute myeloblastic leukemia (AML), mixed lineage leukemia (MLL), acute lymphocytic leukemia, multiple myeloma, eryhthroleukemia, relapsed/refractory follicular lymphoma, Mantle cell lymphoma, marginal B cell lymphoma, primary mediastinal B cell lymphoma, diffuse large B cell lymphoma, peripheral T cell lymphomas and Hodgkin lymphoma. It is administered through oral route. The drug candidate is developed based on the targeting tissue (TARTIS) technology. It acts by targeting Nicotinamide phosphoribosyl transferase (NAMPT). It was under development for the treatment of lymphoplasmacytic lymphoma,
OncoTartis is a biotechnology company that develops drugs to treat various types of cancers. The company offers lead candidate OT-82, an orally available nicotinamide phosphoribosyl transferase inhibitor (NAMPT), which is being developed for treating range of acute myeloid leukemia. It also develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers such as breast, prostate, ovarian, melanoma and hematological malignancies. OncoTartis’ utilizes Tartis, a proprietary integrated drug and target discovery platform for identification of small molecules and shRNAs compounds corresponding to specific genes. The company carries research and development activities in both chemical and biological screenings with cell phenotype-based readout systems. OncoTartis is headquartered in Buffalo, New York, the US.
Quick View OT-82 LOA Data
|Highest Development Stage|